Baiair Pharma Announces RMB 27 Million Strategic Investment in SigeGene to Expand into Small Nucleic Acid Therapeutics

China Interview Network DataQingdaoBaiyang PharmaceuticalCo., Ltd. (Stock Code: 301015) held a board meeting on March 19 to review and approve the proposal for external investment and related-party transactions. The company plans to invest RMB 27 million in cash into SicaGene (Beijing) Biotechnology Co., Ltd., holding 10% of SicaGene's shares post-investment. This transaction is based on an appraisal report issued by an evaluation agency, with SicaGene’s pre-investment valuation at RMB 238 million. According to the agreement, Baiyang Pharmaceutical will gain preferential rights to acquire all of SicaGene's pipeline products or technologies and priority negotiation rights for commercialization benefits worldwide. SicaGene is a biotechnology company focusing on the research and development of single-stranded oligonucleotide (ASO) drugs. Its core product, SG12 injection, has received IND approval, and another product, SG13, has been selected for a national key project. One of the investors, Beijing Mentougou District Baiyang Pharmaceutical Industry Investment Fund, is a related party of the company, making this transaction a related-party transaction. The company stated that this cooperation aims to expand its layout in the small nucleic acid drug field and jointly promote innovative drug development through resource integration. The investment funds come from the company's own resources and will not lead to changes in the scope of the consolidated financial statements, nor is it expected to significantly impact this year's operating performance.